###begin article-title 0
Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 257 260 257 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6</italic>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
Chronic inflammation is a characteristic of Alzheimer's disease (AD). An interaction associated with the risk of AD has been reported between polymorphisms in the regulatory regions of the genes for the pro-inflammatory cytokine, interleukin-6 (IL-6, gene: IL6), and the anti-inflammatory cytokine, interleukin-10 (IL-10, gene: IL10).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
We examined this interaction in the Epistasis Project, a collaboration of 7 AD research groups, contributing DNA samples from 1,757 cases of AD and 6,295 controls.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 93 95 93 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF</italic>
###xml 143 145 143 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 221 225 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 294 297 282 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 304 306 292 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 331 334 319 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 341 343 329 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
We replicated the interaction. For IL6 rs2069837 AA x IL10 rs1800871 CC, the synergy factor (SF) was 1.63 (95% confidence interval: 1.10-2.41, p = 0.01), controlling for centre, age, gender and apolipoprotein E epsilon4 (APOEepsilon4) genotype. Our results are consistent between North Europe (SF = 1.7, p = 0.03) and North Spain (SF = 2.0, p = 0.09). Further replication may require a meta-analysis. However, association due to linkage disequilibrium with other polymorphisms in the regulatory regions of these genes cannot be excluded.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 69 75 <span type="species:ncbi:9606">people</span>
We suggest that dysregulation of both IL-6 and IL-10 in some elderly people, due in part to genetic variations in the two genes, contributes to the development of AD. Thus, inflammation facilitates the onset of sporadic AD.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Alzheimer's disease (AD) is accompanied by a chronic inflammatory process, including activation of microglia and astrocytes that express pro-inflammatory cytokines [1,2]. It is unclear to what extent this inflammation is a reaction to the pathology of AD, and to what extent it contributes to the onset or progression of the disease.
###end p 11
###begin p 12
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 216 217 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 413 417 413 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 421 425 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 635 638 635 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6</italic>
###xml 724 728 724 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
###xml 935 937 935 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1463 1464 1463 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1465 1466 1465 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Two multi-functional cytokines, interleukin-6 (IL-6) and interleukin-10 (IL-10), may be relevant to this question. IL-6 is a potent pro-inflammatory cytokine [3], while IL-10 acts to limit inflammation in the brain [4]. Both are produced by activated microglia and astrocytes [3,4]. Two single nucleotide polymorphisms (SNPs), rs1800795 (-174G/C) and rs1800896 (-1082G/A), in the regulatory regions of the genes, IL6 and IL10, respectively, have been widely studied. However, the ongoing AlzGene meta-analyses of the two SNPs [5] are both currently negative (4 July 2009): pooled odds ratios for Caucasians in single-locus analyses of IL6-174C versus G alleles = 0.93 (95% confidence interval: 0.79-1.08, 14 studies) and of IL10-1082G versus A alleles = 0.91 (0.74-1.11, eight studies). Our own meta-analyses, both by allele and by genotype, confirmed these results and also indicated a high degree of heterogeneity among the studies (p < 0.05 in seven out of eight analyses, data not shown). Such inconsistencies may be due to study differences, e.g. in design or technical or analytical approach. However, the heterogeneity remained in six out of eight analyses after altogether four studies with controls in Hardy-Weinberg disequilibrium were removed. Alternatively, the heterogeneity may reflect true population differences, such as in interactions with other factors, including other genes. Such diverse results have been described as a marker of epistasis [6,7], i.e. where the effect of one polymorphism depends on the genotype at another locus.
###end p 12
###begin p 13
###xml 22 23 22 23 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 57 60 57 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6</italic>
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
Infante et al (2004) [8] reported an interaction between IL6-174G/C and IL10-1082G/A associated with the risk of AD. We therefore set out to replicate this result in the Epistasis Project.
###end p 13
###begin title 14
The Epistasis Project
###end title 14
###begin p 15
###xml 84 85 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Sporadic Alzheimer's disease (AD) is a complex disease, with over 50% heritability [9]. This suggests that its study requires the investigation of interactions between risk factors, particularly genetic factors. The Epistasis Project studies such interactions, mainly those between distinct genetic loci, i.e. epistasis. The project is a collaboration of seven AD research groups: Bonn, Bristol, Nottingham, OPTIMA, Oviedo, Rotterdam and Santander (Table 1). The project aims: first, to replicate genetic interactions that have been reported to affect the risk of sporadic AD; second, to explore other polymorphisms in the relevant genetic regions, ultimately to reveal the true risk loci. The overriding object is to gain insights into AD causality. However, interactions can only be reliably studied with sufficient statistical power and careful study design. The project therefore has these characteristics:-
###end p 15
###begin p 16
Sample-sets used in the Epistasis Project
###end p 16
###begin p 17
AD = Alzheimer's disease
###end p 17
###begin p 18
*from which the samples were drawn.
###end p 18
###begin p 19
###xml 0 6 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 82 84 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 166 168 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
daggerClinical AD cases were diagnosed as "probable AD" by NINCDS-ADRDA criteria [12]; autopsy AD cases were diagnosed as "definite" or "probable" by CERAD criteria [11]; screened controls were free of cognitive impairment; autopsy controls were free of pathology consistent with AD or other dementias; all controls were >/= 60 years of age.
###end p 19
###begin p 20
###xml 0 13 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8225;</sup>
double daggerAge at death or last examination.
###end p 20
###begin title 21
1. Power
###end title 21
###begin p 22
###xml 106 109 106 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 287 289 287 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF</italic>
The project has 1,757 cases of AD and 6,295 elderly controls. These numbers give 99.9% power to detect an SF [10] of 2 between two polymorphisms, each with a minor allele frequency of 20%, when controlling for individual centres (2 below). They give 89.8% power or 48.6% power to detect SFs of 1.5 or 1.25, respectively. Quality control of genotyping reduces the numbers somewhat, depending on the polymorphism.
###end p 22
###begin title 23
2. Selection of sample-sets
###end title 23
###begin p 24
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Only sample-sets drawn from narrow geographical regions with relatively homogeneous, Caucasian populations have been chosen, from seven AD research centres (Table 1 and Additional file 1).
###end p 24
###begin title 25
3. Sample characterisation
###end title 25
###begin p 26
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Cases of AD are either confirmed at autopsy as "definite" or "probable" by CERAD criteria [11], or clinically diagnosed as "probable AD" by NINCDS-ADRDA criteria [12]. Controls are either screened as free of cognitive impairment, or confirmed at autopsy as free of pathology consistent with AD or other dementias.
###end p 26
###begin title 27
4. Matching of cases and controls
###end title 27
###begin p 28
Only cases and controls drawn from the same region are compared, thus controlling for geographical differences, e.g. between North and South Europe.
###end p 28
###begin title 29
5. Candidate interactions
###end title 29
###begin p 30
###xml 191 195 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
Interactions are studied that have prior evidence of an association with AD and a plausible biological hypothesis. Interactions with age (+/- 75 years), gender and apolipoprotein E epsilon4 (APOEepsilon4) genotype are also examined.
###end p 30
###begin title 31
6. Analytical methods
###end title 31
###begin p 32
###xml 24 27 24 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 28 30 28 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
Logistic regression and SF [10] analyses are used. All analyses are controlled for age, gender and APOEepsilon4 genotype. All pooled analyses are also controlled for centre. There is thus no question of controls from one centre (e.g., Rotterdam) being compared with AD cases from another region. Controlling for centre also reduces the relative influence of large subgroups, such as Rotterdam controls, in the pooled result. Where pooled analyses yield significant results, the seven individual centres are also examined for associations with AD, for heterogeneity, and for power to detect the interaction.
###end p 32
###begin p 33
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Table 1 gives the basic characteristics of the seven sample-sets. See Additional file 1 for further information.
###end p 33
###begin p 34
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 321 323 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 344 346 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 363 364 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 387 389 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 420 422 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
To select the interactions for study, a survey of over 100 published claims and suggestions of epistasis in sporadic AD was undertaken [13]. The interactions finally chosen are involved in various networks that are widely considered to contribute to the development of AD: lipid metabolism [14], beta-amyloid metabolism [15], oxidative stress [16], inflammation [1], insulin metabolism [17] and homocysteine metabolism [18]. Positive results should therefore deliver insights into the causes of AD.
###end p 34
###begin title 35
Methods
###end title 35
###begin p 36
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Basic information on the 1,757 cases of AD and the 6,295 controls from the seven centres is given above and in Table 1, and fuller details are provided in Additional file 1.
###end p 36
###begin p 37
Genotyping for the six centres other than Rotterdam was performed at the Wellcome Trust Sanger Institute, using the iPLEX Gold assay (Sequenom Inc.). Whole genome amplified DNA was used for 82% of samples; genomic DNA was used for the 18% of samples that were not suitable for whole genome amplification. A Sequenom iPLEX, designed for quality control purposes, was used to assess genotype concordance between genomic and whole genome amplified DNA for 168 individuals. Assays for all SNPs were designed using the eXTEND suite and MassARRAY Assay Design software version 3.1 (Sequenom Inc.). Samples were amplified in multiplexed PCR reactions before allele specific extension. Allelic discrimination was obtained by analysis with a MassARRAY Analyzer Compact mass spectrometer. Genotypes were automatically assigned and manually confirmed using MassArray TyperAnalyzer software version 4.0 (Sequenom Inc.). Gender markers were included in all iPLEX assays as a quality control metric for confirmation of plate/sample identity. Genotyping of SNPs rs1800871, rs2069837 and rs3024505 was carried out using the KASPar technology by KBioscience .
###end p 37
###begin p 38
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Genotyping in the Rotterdam cohort was done on Version 3 Illumina-Infinium-II HumanHap550 SNP array (Illumina, San Diego, USA) and additionally, SNPs were imputed using MACH software  with HapMap CEU Release 22 as a reference [19]. The reliability of imputation was estimated for each imputed SNP with the ratio of expected and observed dosage variance (O/E ratio). Only samples with high-quality extracted DNA were genotyped; 5974 were available with good quality genotyping data; 5502 of these had reliable phenotypes. For the Epistasis Project, 52 genotyped SNPs and 116 imputed SNPs were selected.
###end p 38
###begin p 39
###xml 61 64 61 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 570 573 564 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 742 745 736 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 841 843 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 885 887 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
We assessed associations with logistic regression models and SF analysis [10], controlling for age, gender, APOEepsilon4 and study centre, using R Version 2.6.1 (R Foundation for Statistical Computing, Vienna, Austria). Heterogeneity between centres was controlled by fitting a fixed effect corresponding to contrasts between the baseline centre and the six other centres (having compared models with fixed- and random-effect terms in centre, goodness of fit was measured using Akaike's Information Criterion, which favoured using fixed effects only). Where the overall SF was significant at p < 0.05, the seven individual centres and the two geographical regions, North Europe and North Spain, were also examined. Power calculations were by SF analysis. Meta-analyses were performed using the random-effect method of DerSimonian and Laird [20] and the heterogeneity test of Armitage [21]. Comparisons of allelic frequencies between North Spain and North Europe were by Fisher's exact test. We compared the medians of the age distributions of AD and control groups using the Wilcoxon-Mann-Whitney test. Linkage disequilibrium data were estimated using the R genetics library . All tests of significance were two-sided.
###end p 39
###begin title 40
Results
###end title 40
###begin p 41
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 191 194 191 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6</italic>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
###xml 428 432 428 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 461 466 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 498 502 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 516 521 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 608 609 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
We replicated the interaction reported by Infante et al (2004) [8] between IL6 rs1800795 (-174G/C) and IL10 rs1800896 (-1082G/A) (below). In the Rotterdam cohort, we examined altogether five IL6-related SNPs, rs1800797, rs1800795, rs2069837, rs2069840 and rs2069845, and four IL10-related SNPs, rs1800896, rs1800871, rs3024498 and rs3024505. In that preliminary study, we found that the strongest interactions were seen between IL6 rs2069837 (intron 2 A/G) and IL10 rs1800871 (-819C/T) and between IL6 rs2069837 and IL10 rs3024505 (3' C/T) (data not shown). We therefore studied the five SNPs shown in Table 2 in all seven sample-sets.
###end p 41
###begin p 42
Studied SNPs
###end p 42
###begin p 43
###xml 146 150 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
SNP = single nucleotide polymorphism; LD = linkage disequilibrium; D' = ratio of observed LD to maximum possible LD; r = correlation coefficient; IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively.
###end p 43
###begin p 44
###xml 65 66 65 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 302 305 302 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6</italic>
###xml 345 347 345 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 364 368 364 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 428 433 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 445 446 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Hardy-Weinberg analysis was performed for the five SNPs of Table 2 in both cases and controls of the Rotterdam samples, genotyped by Rotterdam, and of the samples from the other six centres, genotyped by the Sanger Institute. As expected by chance, one of these 20 analyses resulted in disequilibrium: IL6-174G/C in AD cases of the six centres (p = 0.02). The two IL6 SNPs were in linkage disequilibrium (LD), as were the three IL10 SNPs (Table 2). The allelic frequencies differed significantly between North Europe (Bonn, Bristol, Nottingham, OPTIMA and Rotterdam) and North Spain (Oviedo and Santander) in four out of the five SNPs (Table 2).
###end p 44
###begin p 45
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 204 208 204 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 315 320 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF p </italic>
###xml 365 366 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 432 433 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 520 523 514 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 622 626 616 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 651 652 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 665 667 659 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 696 701 690 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 712 714 706 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 749 753 743 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 769 773 763 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
###xml 808 811 802 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 856 858 850 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
We examined the potential associations with AD of the six interactions generated between the two IL6 SNPs and the three IL10 SNPs in our overall dataset (Table 3), controlling for centre, age, gender and APOEepsilon4 genotype (as in all association analyses). Three of the six interactions were associated with AD: SF p < 0.05. The first interaction shown in Table 3 is effectively identical to that reported by Infante et al 2004 [8]; we have merely reversed the first genotype, i.e. CC rather than GC + GG, to give an SF of 1.56, rather than its inverse, 0.64, for easier comparison with the other interactions. The two IL6 genotypes shown in Table 3 were in LD (p < 0.0001), as were the three IL10 genotypes (p < 0.0001). The interaction between IL6 intron 2 AA and IL10-819CC was slightly the strongest: SF = 1.63 (95% confidence interval = 1.10-2.41, p = 0.01). All further analysis was therefore restricted to that interaction.
###end p 45
###begin p 46
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
Potential interactions between IL6 SNPs and IL10 SNPs in the risk of AD
###end p 46
###begin p 47
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively; SNPs = single nucleotide polymorphisms; AD = Alzheimer's disease; CI = confidence interval; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; APOEepsilon4 = apolipoprotein E epsilon4.
###end p 47
###begin p 48
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
*All analyses controlled for centre, age, gender and APOEepsilon4 genotype.
###end p 48
###begin p 49
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
###xml 174 178 174 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 232 234 232 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 270 272 270 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 383 385 383 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 410 412 410 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Table 4 shows the effect of each of the two factors in that interaction on the association with AD of the other factor. The presence of IL10-819CC changed the association of IL6 intron 2 AA with AD from negative (odds ratio = 0.86, p = 0.30) to risk (odds ratio = 1.38, p = 0.02), while the presence of the latter removed the protective association of the former (odds ratio = 0.63, p = 0.01, changed to 1.08, p = 0.32).
###end p 49
###begin p 50
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
Odds ratios of Alzheimer's disease for two IL6 and IL10 SNPs, stratified by each other
###end p 50
###begin p 51
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 191 195 191 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively; AD = Alzheimer's disease; CI = confidence interval; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; APOEepsilon4 = apolipoprotein E epsilon4.
###end p 51
###begin p 52
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
*All analyses controlled for centre, age, gender and APOEepsilon4 genotype.
###end p 52
###begin p 53
###xml 146 149 146 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 192 194 192 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 232 235 232 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 327 330 327 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 337 339 337 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 368 371 368 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
There was significant heterogeneity between the centres, and the interaction was only significant in one of the seven centres, Rotterdam, with an SF of 3.0 (95% confidence interval = 1.6-5.8, p = 0.0007). But the power to detect an SF of 1.6 was low in each centre, ranging from below 10% to 40%. The results for North Europe (SF = 1.7, p = 0.03) and for North Spain (SF = 2.0, p = 0.09) were consistent (Table 5).
###end p 53
###begin p 54
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
Interaction between IL6 rs2069837 AA vs G+ and IL10 rs1800871 CC vs T+, by region
###end p 54
###begin p 55
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 191 195 191 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; CI = confidence interval; AD = Alzheimer's disease; APOEepsilon4 = apolipoprotein E epsilon4.
###end p 55
###begin p 56
*To detect a synergy factor of 1.6 (as in the overall dataset) at 0.05.
###end p 56
###begin p 57
###xml 0 6 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 58 62 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
daggerAll analyses controlled for centre, age, gender and APOEepsilon4 genotype.
###end p 57
###begin p 58
###xml 0 13 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8225;</sup>
double daggerNorth Europe = Rotterdam, Bonn, OPTIMA, Nottingham and Bristol; North Spain = Santander and Oviedo.
###end p 58
###begin p 59
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 161 164 161 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF </italic>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 25 28 <span type="species:ncbi:9606">men</span>
###xml 36 41 <span type="species:ncbi:9606">women</span>
Results were similar for men as for women (data not shown). The interaction was slightly stronger in older subjects: SF for > 75 years = 1.71 (1.05-2.78, 0.03); SF for < 75 years = 1.27 (0.56-2.87, 0.57). However, there was no 3-way interaction with age. Nor did we find a significant interaction with APOEepsilon4.
###end p 59
###begin title 60
Discussion
###end title 60
###begin p 61
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 206 210 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 265 267 265 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF</italic>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 761 762 761 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
In our whole dataset of over 7,500 samples, we have replicated both the interaction reported by Infante et al 2004 [8] and also that found in our preliminary study in the Rotterdam dataset, between SNPs of IL6 and IL10 (Table 3). Both interactions gave significant SFs of approximately 1.6. There was significant heterogeneity between centres, which was unsurprising since only two, Rotterdam and Santander, had > 20% power to detect these interactions. But the results for the two main regions, North Europe and North Spain, were consistent (Table 5). We conclude that this is likely to be a true effect, but not a very strong one. As in any example of true epistasis, the presence or absence of one factor critically influenced the effect of the other (Table 4).
###end p 61
###begin p 62
Further replication will require a dataset at least as large, with appropriate statistical control for differences between individual sample-sets. Underpowered studies are unhelpful, since chance can produce misleading results in such cases. This criticism may apply to a previous study of this interaction that had power of < 2% to detect it. Even the large Rotterdam Study, with 395 cases of AD and 5,111 controls, only had 40% power to detect this interaction. Thus, further replication may require a meta-analysis.
###end p 62
###begin title 63
IL-6 in age-related decline and in AD
###end title 63
###begin p 64
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 687 689 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 148 154 <span type="species:ncbi:9606">humans</span>
There is much evidence that chronic, low-grade overexpression of IL-6 contributes to age-related decline. Blood levels of IL-6 can rise with age in humans [22-24]. Raised levels are associated with various age-related conditions, including risk of cognitive decline in some studies [25,26], but not in all [27]. Raised levels have been consistently associated with increased mortality in several large prospective studies [28-31]. Raised levels have also been associated with various conditions considered to be risk factors for dementia and/or AD: subclinical and clinical cardiovascular disease and the risk thereof [32-34], type 2 diabetes and its risk [35,36], psychological stress [37] and the damage following stroke (IL-6 also increased in CSF) [38,39].
###end p 64
###begin p 65
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
Further, raised blood levels of IL-6 have often been associated with AD [40-42] and also with the risk of AD [43], although not in all studies [44,45]. Post-mortem studies, although small, have generally reported increased IL-6 levels or changed IL-6 distribution in AD brain [46-49], with one exception [50]. IL-6 was found not only in plaques, but also around the bodies of isocortical neurones, only in AD [46]. This evidence and that above suggest that dysregulation of IL-6 contributes to the development of AD.
###end p 65
###begin title 66
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6</italic>
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
A potential interaction between IL6 and IL10
###end title 66
###begin p 67
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 87 88 87 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 288 292 288 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
###xml 515 524 515 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 617 621 617 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
###xml 638 643 638 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 </italic>
###xml 904 907 904 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6</italic>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 919 921 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 927 931 927 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
###xml 940 942 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 951 955 951 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
###xml 965 967 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 968 970 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1228 1231 1228 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6</italic>
###xml 1243 1247 1243 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
###xml 1277 1286 1277 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1393 1397 1393 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
###xml 1435 1444 1435 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1476 1478 1476 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1479 1481 1479 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1503 1505 1503 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 1506 1508 1506 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 1564 1566 1564 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1567 1569 1567 1569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 1707 1709 1707 1709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 1773 1792 1773 1792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10 -1082G+/-819CC</italic>
###xml 1834 1838 1834 1838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6 </italic>
Both IL-6 and IL-10 are produced by activated microglia and astrocytes (reviewed in [3,4]). However, in contrast to IL-6, IL-10 acts to limit inflammation in the brain. IL-10 inhibits the production of IL-6 [51,52] and its receptor [53]. Thus, certain combinations of genetic variants of IL6 and IL10, i.e. those associated with high production of IL-6 combined with those associated with low production of IL-10, may contribute to the dysregulation of inflammation. High heritability (> 50%) has been reported for in vitro stimulated production of both IL-6 and IL-10 [54]. The functions of two of our studied SNPs, IL6 intron 2 A/G and IL10 3' C/T have not yet been investigated. Thus we cannot rule out that they might have effects on transcription or post-transcriptional processing. Alternatively, they may be in linkage disequilibrium with other, functional variants. On the other hand, studies of IL6-174G/C [55,56], of IL10-819C/T [57] and of IL10-1082G/A [58-60] have reported that these SNPs affect transcription or are in linkage disequilibrium with those that do. However, it may be premature to designate any particular alleles as high or low producers, since there have been contrasting results for the effects of IL6-174G/C and IL10-1082G/A on transcription, on in vitro stimulated production and on blood levels of the respective proteins. But most studies have associated the IL10-1082GG genotype at least with higher in vitro stimulated production of IL-10 [61-64], although not all, [65,66] and results have varied with experimental conditions [64,66]. It appears that several SNPs in the regulatory regions of each gene affect transcription in an interactive and tissue-specific manner [56]. Indeed, we note that in our dataset the 2-SNP combination of IL10 -1082G+/-819CC has a slightly stronger interaction with IL6 than that of either SNP alone (data not shown).
###end p 67
###begin title 68
Conclusion
###end title 68
###begin p 69
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 167 173 <span type="species:ncbi:9606">people</span>
We conclude that an interaction between IL-6 and IL-10 is plausible; that dysregulation of the two genes contributes to chronic low-grade inflammation in some elderly people and thus to the risk of AD; and that certain combinations of genetic variants in the regulatory regions of the two genes are conducive to this dysregulation. But in view of the linkage disequilibrium in the region of each gene (Table 2), we cannot conclude that we have yet found the true risk polymorphisms. However, we suggest that our results are consistent with the contribution of inflammation to the onset of AD.
###end p 69
###begin title 70
Abbreviations
###end title 70
###begin p 71
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 180 183 168 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6</italic>
###xml 236 240 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL10</italic>
###xml 470 472 458 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF</italic>
AD: Alzheimer's disease; APOEepsilon4: apolipoprotein E epsilon4; CERAD: Consortium to Establish a Registry for Alzheimer's Disease; CSF: cerebrospinal fluid; IL-6: interleukin-6; IL6: the gene for interleukin-6; IL-10: interleukin-10; IL10: the gene for interleukin-10; NINCDS-ADRDA: National Institute of Neurological, Communicative Diseases and Stroke-Alzheimer's Disease and Related Diseases Association; OPTIMA: the Oxford Project to Investigate Memory and Ageing; SF: synergy factor; SNP: single nucleotide polymorphism.
###end p 71
###begin title 72
Competing interests
###end title 72
###begin p 73
The authors declare that they have no competing interests.
###end p 73
###begin title 74
Authors' contributions
###end title 74
###begin p 75
All authors contributed to the design of the study. In addition, ADS and DJL set up the Epistasis Project, with the help of the other authors. ADS and DJL decided on the strategy of the Epistasis Project, with the help of CMvD, OC, KM, PK, R Heun, MC-B, DRW and EC. ADS, DJL, CMvD, OC, KM, PK, R Heun, MC-B, DRW and EC chose the genetic interactions to study. OC produced the hypothesis for this study. KM and OB gave extensive advice on the choice of SNPs to study. DJL made the final selection of polymorphisms. HK, R Harrison, KM, DRW, EC and IM provided DNA for genotyping. CMvD, YSA, AA-V and MS provided the data for the preliminary study. DRW gave technical advice throughout. RG and NH were responsible for the genotyping of 6 sample-sets. AA-V was responsible for the Rotterdam genotyping. MC-B and DJL decided on the analytical approach. MC-B and YSA advised on statistics throughout. DJL and MGL performed the analysis. DJL drafted the manuscript. OC submitted the manuscript and is responsible for correspondence. All authors read the manuscript, studied it critically for its intellectual content and approved the final draft.
###end p 75
###begin title 76
Supplementary Material
###end title 76
###begin title 77
Additional file 1
###end title 77
###begin p 78
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The seven centres of the Epistasis Project</bold>
The seven centres of the Epistasis Project.
###end p 78
###begin p 79
Click here for file
###end p 79
###begin title 80
Acknowledgements
###end title 80
###begin p 81
###xml 269 274 <span type="species:ncbi:9606">Child</span>
###xml 560 565 <span type="species:ncbi:9606">Child</span>
We are most grateful to the Moulton Charitable Foundation for a grant to fund the Epistasis Project and to all those who have provided support for the individual clinical studies. GW was partly supported by the NIHR Biomedical Research Centre, Oxford. UCL Institute of Child Health receives funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. The Centre for Paediatric Epidemiology and Biostatistics also benefits from funding support from the Medical Research Council in its capacity as the MRC Centre of Epidemiology for Child Health (G0400546).
###end p 81
###begin article-title 82
Inflammation and Alzheimer's disease
###end article-title 82
###begin article-title 83
Inflammation and Alzheimer's disease pathogenesis
###end article-title 83
###begin article-title 84
Physiological and pathological roles of interleukin-6 in the central nervous system
###end article-title 84
###begin article-title 85
Interleukin-10 in the brain
###end article-title 85
###begin article-title 86
Systematic meta-analyses of Alzheimer disease genetic association studies: the Alzgene database
###end article-title 86
###begin article-title 87
Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis
###end article-title 87
###begin article-title 88
Epistasis, complex traits, and mapping genes
###end article-title 88
###begin article-title 89
Gene-gene interaction between interleukin-6 and interleukin-10 reduces AD risk
###end article-title 89
###begin article-title 90
The role of heredity in late-onset Alzheimer disease and vascular dementia - a twin study
###end article-title 90
###begin article-title 91
The synergy factor: a statistic to measure interactions in complex diseases
###end article-title 91
###begin article-title 92
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
###end article-title 92
###begin article-title 93
###xml 128 133 <span type="species:ncbi:9606">Human</span>
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease
###end article-title 93
###begin article-title 94
Epistasis in sporadic Alzheimer's disease
###end article-title 94
###begin article-title 95
Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis
###end article-title 95
###begin article-title 96
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics
###end article-title 96
###begin article-title 97
Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?
###end article-title 97
###begin article-title 98
The role of metabolic disorders in Alzheimer disease and vascular dementia
###end article-title 98
###begin article-title 99
The worldwide challenge of the dementias: a role for B vitamins and homocysteine?
###end article-title 99
###begin article-title 100
Genomewide association studies of stroke
###end article-title 100
###begin article-title 101
Meta-analysis in clinical trials
###end article-title 101
###begin article-title 102
Interleukin-6: a cytokine for gerontologists
###end article-title 102
###begin article-title 103
###xml 54 61 <span type="species:ncbi:9606">persons</span>
Interleukin-6 and selected plasma proteins in healthy persons of different ages
###end article-title 103
###begin article-title 104
The influence of age and gender on serum dehydroepiandrosterone sulphate (DHEA-S), IL-6, IL-6 soluble receptor (IL-6 sR) and transforming growth factor beta1 (TGF-beta1) levels in normal healthy blood donors
###end article-title 104
###begin article-title 105
Interleukin-6 and risk of cognitive decline
###end article-title 105
###begin article-title 106
Inflammatory markers and cognition in well-functioning African-American and white elders
###end article-title 106
###begin article-title 107
###xml 59 66 <span type="species:ncbi:9606">persons</span>
Serum inflammatory proteins and cognitive decline in older persons
###end article-title 107
###begin article-title 108
Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly
###end article-title 108
###begin article-title 109
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
###end article-title 109
###begin article-title 110
###xml 127 134 <span type="species:ncbi:9606">persons</span>
Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons
###end article-title 110
###begin article-title 111
###xml 70 75 <span type="species:ncbi:9606">women</span>
###xml 81 86 <span type="species:ncbi:9606">Women</span>
Cardiovascular disease, interleukin-6, and risk of mortality in older women: the Women's Health and Aging Study
###end article-title 111
###begin article-title 112
Inflammatory markers and onset of cardiovascular events: results from the Health ABC study
###end article-title 112
###begin article-title 113
Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] study)
###end article-title 113
###begin article-title 114
###xml 108 111 <span type="species:ncbi:9606">men</span>
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
###end article-title 114
###begin article-title 115
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
###end article-title 115
###begin article-title 116
###xml 127 135 <span type="species:ncbi:9606">patients</span>
Interleukin-6-174G>C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients
###end article-title 116
###begin article-title 117
Chronic stress and age-related increases in the proinflammatory cytokine IL-6
###end article-title 117
###begin article-title 118
Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target
###end article-title 118
###begin article-title 119
Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke
###end article-title 119
###begin article-title 120
###xml 44 49 <span type="species:ncbi:9606">women</span>
Plasma beta amyloid and cytokine profile in women with Alzheimer's disease
###end article-title 120
###begin article-title 121
Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease
###end article-title 121
###begin article-title 122
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?
###end article-title 122
###begin article-title 123
Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study
###end article-title 123
###begin article-title 124
Blood inflammatory markers and risk of dementia: the Conselice Study of Brain Aging
###end article-title 124
###begin article-title 125
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease
###end article-title 125
###begin article-title 126
Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices
###end article-title 126
###begin article-title 127
Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain
###end article-title 127
###begin article-title 128
Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia
###end article-title 128
###begin article-title 129
Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein
###end article-title 129
###begin article-title 130
Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin
###end article-title 130
###begin article-title 131
Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NFkappa B
###end article-title 131
###begin article-title 132
###xml 97 103 <span type="species:ncbi:10090">murine</span>
###xml 120 125 <span type="species:ncbi:9606">human</span>
IL-4, IL-10 and IL-13 modulate Abeta (1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line
###end article-title 132
###begin article-title 133
Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia
###end article-title 133
###begin article-title 134
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cytokine response to ex vivo amyloid-beta stimulation is mediated by genetic factors
###end article-title 134
###begin article-title 135
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis
###end article-title 135
###begin article-title 136
Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation
###end article-title 136
###begin article-title 137
###xml 127 147 127 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Helicobacter pylori </italic>
###xml 127 146 <span type="species:ncbi:210">Helicobacter pylori</span>
Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection
###end article-title 137
###begin article-title 138
Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis
###end article-title 138
###begin article-title 139
The interleukin-10 -1082 G/A polymorphism: allele frequency in different populations and functional significance
###end article-title 139
###begin article-title 140
Differential regulation of interleukin-10 production by genetic and environmental factors - a twin study
###end article-title 140
###begin article-title 141
Cytokine (TNFalpha, LT alpha l and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies
###end article-title 141
###begin article-title 142
Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms
###end article-title 142
###begin article-title 143
An investigation of polymorphism in the interleukin-10 gene promoter
###end article-title 143
###begin article-title 144
IL-12 and IL-10 polymorphisms and their effects on cytokine production
###end article-title 144
###begin article-title 145
Are differences in interleukin 10 production associated with joint damage?
###end article-title 145
###begin article-title 146
Are cytokine gene polymorphisms related to in vitro cytokine production profiles?
###end article-title 146

